ERYTECH Pharma (Euronext: ERYP, Nasdaq: ERYP) will host a Third Quarter 2020 conference call on November 6, 2020, at 2:30 PM CET / 8:30 AM EST. The call aims to discuss operational highlights. Participants can join via dedicated teleconferencing numbers, with an accessible live webcast available online. An archived replay will be accessible for 7 days post-call. ERYTECH is focused on developing red blood cell-based therapies, with its lead product, eryaspase, in clinical trials for various cancers.
ERYTECH Pharma (Nasdaq & Euronext: ERYP) has appointed Dr. Stewart Craig as Chief Technical Officer, enhancing its executive team. Dr. Craig, with 35 years of experience, will drive manufacturing and supply chain operations for ERYTECH's innovative red blood cell-based cancer therapies. His prior roles include key positions at leading cell and gene therapy companies. With ERYTECH's lead candidate, eryaspase, nearing pivotal clinical trials for pancreatic and breast cancers, Dr. Craig's expertise is vital for achieving operational readiness and commercial success.
Rhea-AI reports on ERYP, listed on Euronext Paris and Nasdaq. As of September 30, 2020, the company has 18,995,590 shares out, with gross voting rights at 20,530,281. The net voting rights stand at 20,527,781. This data reflects a period of stability in share capital with no significant changes in voting rights.
The provided information is crucial for investors monitoring ERYP's market performance, emphasizing transparency in shareholding structure.
ERYTECH Pharma reported significant progress in its clinical trials and financial status as of June 30, 2020. The pivotal TRYbeCA-1 Phase 3 trial for metastatic pancreatic cancer is over 90% enrolled, with interim superiority analysis slated for Q1 2021. The FDA granted Fast Track designation for its lead product candidate, eryaspase. Financially, the company holds €45.4 million in cash, down from €73.2 million a year ago, primarily due to increased clinical expenses, resulting in a net loss of €35 million, up 19% year-over-year. Final data from a Phase 2 trial in leukemia is also expected by year-end.
ERYTECH Pharma announced an at-the-market program to issue and sell up to $30 million in ordinary shares as American Depositary Shares (ADSs) through Cowen. This initiative, approved at the Annual General Meeting on June 26, 2020, allows for sales at prevailing market prices without shareholders’ preferential rights, subject to a 20% dilution cap. The company aims to utilize the proceeds for research and development and general corporate purposes. The program will remain effective until September 21, 2023, unless terminated earlier.
ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP) will host its Q2 2020 conference call on September 22, 2020, at 2:30 PM CEST/8:30 AM EST to discuss operational highlights. Accessibility includes a teleconference with ID: 8585556# and a live webcast at this link. An archived replay will be available for 7 days post-call. ERYTECH develops innovative red blood cell-based therapeutics, notably eryaspase, targeting cancer cell metabolism.
ERYTECH Pharma (Nasdaq & Euronext: ERYP) has enrolled over 450 of the planned 500 patients in its TRYbeCA-1 Phase 3 trial, evaluating eryaspase for second-line metastatic pancreatic cancer. An interim superiority analysis is anticipated by year-end 2020, with outcomes determining whether the trial continues towards a final analysis in 2021 or is stopped for efficacy. The FDA has granted eryaspase Fast Track Designation. The company will host a KOL call on September 29, 2020, featuring Dr. Manuel Hidalgo discussing pancreatic cancer treatment and an update on eryaspase.
On September 14, 2020, ERYP (Euronext Paris and Nasdaq Global) released its shareholder update, detailing the share capital and voting rights as of August 31, 2020. The total shares composing the capital reached 18,301,621, while the gross voting rights rose to 19,836,312. The document highlights the evolution of these figures from December 31, 2019, through the reporting period. This update is crucial for shareholders as it provides transparency regarding voting rights and share distribution.
The press release from Lyon, France on August 6, 2020, provides key updates regarding the share capital and voting rights of the company ERYP. As of July 31, 2020, the total shares amount to 18,081,843, with 19,758,342 total gross voting rights. The net voting rights stand at 19,755,842. This update is crucial for investors as it reflects the shareholder structure and potential voting power within the company, impacting corporate governance and strategic decisions.
On July 10, 2020, ERYP reports updated shareholding data as of June 30, 2020. The total shares amounted to 17,956,115, with gross voting rights at 19,511,885, and net voting rights at 19,509,385.
For prior months, total shares remained constant at 17,940,035 from December 31, 2019, until May 30, 2020, with slight fluctuations in voting rights. This press release adheres to Article 223-16 of the French Autorité des Marchés Financiers regulations.